If you have been reading about AEDG and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
Normal human hemoglobins are tetrameric proteins composed of two pairs of globin chains, each of which contains one alpha-like (α) globin and one beta-like (β) globin. Each globin chain is associated with an iron-containing heme moiety. Throughout life, the synthesis of the α and the β chains is balanced so that their ratio is relatively constant and there is no excess of either type. The specific α and β chains that are incorporated into Hb are highly regulated during development:
== Uses until 2005 == In the United States, the FDA approved valdecoxib for the treatment of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea. Valdecoxib was also used off-label for controlling acute pain and various types of surgical pain.
However, urea-formaldehyde resin itself has been suggested as appropriate for use in feed for some non-ruminants in at least one UN FAO report, suggesting its use as a binder in feed pellets in aquaculture. There is at least one report of inexpensively priced rice protein concentrate (feed grade) containing non-protein nitrogen being marketed for use in non-ruminants dating back to 2005. In a news item on its website, Jiangyin Hetai Industrial Co., Ltd. warned its customers of low-priced "PSEUDO rice protein" for sale in the market by another unnamed supplier, noting that the contaminant could be detected by analyzing the isoelectric point. It is not clear from that report whether the contaminant in that case was melamine or some other non-protein nitrogen source or whether any contaminated rice protein concentrate made it into the food supply at that time. On 18 April 2007, an ad was posted on the trading website Alibaba.com selling "Esb protein powder" in Xuzhou Anying's name. The product is said to be protein in nature and suitable for livestock and poultry feed, yet claims a crude protein content of 160–300%. It also mentions in passing the product makes use of "NPN" which is an acronym for non-protein nitrogen. Similar ads were placed on other websites, some dated as early as 31 October 2005. Products with similar descriptions were also sold as "EM bacterium active protein forage" by Shandong Binzhou Xinpeng Biosciences Company and "HP protein powder" by Shandong Jinan Together Biologic Technology Development Company.
=== Books === Heseltine's book Where There's A Will was written by a team of ghostwriters directed by Keith Hampson and Julian Haviland (former political editor of ITN and The Times). Academics, businessmen and economists contributed, and he often had them thresh out ideas in front of him. "He acquires by social intercourse the knowledge that other people acquire by reading", one adviser commented. The collated drafts were then rewritten by Haviland to "give it one voice". Hugo Young called it "the most impressive [book of its kind] I've read by a modern Conservative". Heseltine's second book, The Challenge of Europe: Can Britain Win?, appeared in 1989. Heseltine was in close touch with President of the European Commission Jacques Delors, who paid a 3-hour visit to his Victoria office, diplomats Nicholas Henderson and Antony Acland and economist Christopher Johnson, who is thought to have persuaded him of the merits of European monetary union. The book won a £10,000 Adolphe Bentincke prize for advancing European unity. Heseltine was a qualified supporter of the social charter (a stronger precursor to the Social Chapter from which John Major would later opt out in the Maastricht Treaty). He was seen as devoted to Europe as a matter of what he perceived as Britain's self-interest, not on an emotional level like Edward Heath, Roy Jenkins or Kenneth Clarke.
Sources: en.wikipedia.org
In mass spectrometry, Orbitrap is an ion trap mass analyzer consisting of an outer barrel-like electrode and a coaxial inner spindle-like electrode that traps ions in an orbital motion around the spindle. The image current from the trapped ions is detected and converted to a mass spectrum by first using the Fourier transform of time domain of the harmonic to create a frequency signal which is converted to mass.
However, urea-formaldehyde resin itself has been suggested as appropriate for use in feed for some non-ruminants in at least one UN FAO report, suggesting its use as a binder in feed pellets in aquaculture. There is at least one report of inexpensively priced rice protein concentrate (feed grade) containing non-protein nitrogen being marketed for use in non-ruminants dating back to 2005. In a news item on its website, Jiangyin Hetai Industrial Co., Ltd. warned its customers of low-priced "PSEUDO rice protein" for sale in the market by another unnamed supplier, noting that the contaminant could be detected by analyzing the isoelectric point. It is not clear from that report whether the contaminant in that case was melamine or some other non-protein nitrogen source or whether any contaminated rice protein concentrate made it into the food supply at that time. On 18 April 2007, an ad was posted on the trading website Alibaba.com selling "Esb protein powder" in Xuzhou Anying's name. The product is said to be protein in nature and suitable for livestock and poultry feed, yet claims a crude protein content of 160–300%. It also mentions in passing the product makes use of "NPN" which is an acronym for non-protein nitrogen. Similar ads were placed on other websites, some dated as early as 31 October 2005. Products with similar descriptions were also sold as "EM bacterium active protein forage" by Shandong Binzhou Xinpeng Biosciences Company and "HP protein powder" by Shandong Jinan Together Biologic Technology Development Company.
==== Industrial policy ==== Following the 1992 general election he was appointed Secretary of State for Trade and Industry, choosing to be known by the title, dormant since 1974, of "President of the Board of Trade". He insisted on being addressed as "President" (not "Mr President") and being referred to as "the President". The board had not met since 1850, but it did not need to as it had a quorum of one. On the backbenches Heseltine had praised the Japanese MITI, and had been planning a book on the subject. He promised to intervene "before breakfast, dinner and tea" to help British companies, but had little opportunity for intervention as the DTI budget had dropped from over £3bn in the early 1980s to £1bn in 1992–1993, a fifth the budget of the Welsh Office. NEDO, which had been set up to coordinate industrial policy in the early 1960s, was abolished by Chancellor Norman Lamont in June 1992, although Heseltine was able to absorb some of the staff into the DTI to set up working parties to shadow specific industries. His junior ministers were Neil Hamilton and Edward Leigh, both Thatcherites. Gordon Brown mocked him (6 July 1992) as having "absolute power over a department which has become absolutely powerless" and "the tiger that was once the king of the jungle is now just the fireside rug – decorative and ostentatious, but essentially there to be walked all over".
=== Awards and distinctions === As of 2022, Palmer has four active RO1's from the National Institutes of Health for bioengineering research projects. He has multiple collaborations from research labs across the U.S. In 2021, Palmer received the Gaden Award from the Biotechnology & Bioengineering (journal) in recognition for a truly outstanding paper. In 2015, Palmer was inducted fellow of the American Institute for Medical and Biological Engineering "for pioneering advances in engineering novel hemoglobin-based oxygen carriers for use as red blood cell substitutes in transfusion medicine." In 2008, Palmer received the Lloyd Noel Ferguson Young Scientist award from the National Organization for the Professional Advancement of Chemists and Chemical Engineers (NOBCHE). In 2001, Palmer was a recipient of the National Science Foundation CAREER Award for "engineering artificial cells.”
Kennedy and Senator Cindy Hyde-Smith passed a Congressional Review Act resolution of disapproval to eliminate a Biden-era Bureau of Ocean Energy Management rule that required oil companies to conduct archaeological reviews of the ocean floor to identify objects, such as shipwrecks or other cultural remains. President Trump signed the resolution in March 2025, formally voiding the rule. In May 2025, Kennedy used the Congressional Review Act to eliminate a Biden-era federal rule that prohibited expedited bank mergers through the Office of the Comptroller of the Currency. Kennedy and Senator Gary Peters introduced the Ending Improper Payments to Deceased People Act, a bill that expanded the Treasury Department's access to the Social Security Administration's full Death Master File to ensure that dead people would not continue to receive payments from the federal government. This bill made permanent the trial program established under the Stopping Improper Payments to Deceased People Act, which passed in 2020. The legislation, which became law in February 2026, is credited with preventing $99 million in payments to dead people.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.